Novocellbio is a leading company in the development of immunotherapeutic drugs using self-NK cells. Through continuous R & D investment, we are securing new technologies and improving technological competitiveness. We are not only developing our own technologies from cultivation techniques to developing reagents, but we also want to leap to become a company specialized in immune cell therapy.

From 2018, we will collaborate with leading university hospitals and research centers to develop various immune cell therapy techniques and develop therapeutic agents for degenerative brain diseases.

In the future, we will do our best to secure global technology leadership by adding cultivation technology and advanced research on advanced medicine to the structure of therapeutic drug business using immune cells.

Novocellbio is strengthening its corporate competitiveness through continuous R & D investment. R & D costs will be set at 20% of sales, and we will continue to research and develop various immune cell therapy technologies in the future.

The research and development activities of the Novocellbio will be conducted in cooperation with R & D center of our institute, hospital immunotherapy center, and university-centered research and development center. We will further strengthen our global technology leadership through collaboration among centers.

The research and development activities of the Novocellbio will be conducted in cooperation with R & D center of our institute, hospital immunotherapy center, and university-centered research and development center. We will further strengthen our global technology leadership through collaboration among centers.